U.S. patent application number 09/896361 was filed with the patent office on 2002-04-11 for combinations of ssri and estrogenic agents.
This patent application is currently assigned to American Home Products Corporation. Invention is credited to Jenkins, Simon N..
Application Number | 20020042432 09/896361 |
Document ID | / |
Family ID | 26910986 |
Filed Date | 2002-04-11 |
United States Patent
Application |
20020042432 |
Kind Code |
A1 |
Jenkins, Simon N. |
April 11, 2002 |
Combinations of SSRI and estrogenic agents
Abstract
This invention comprises methods of depression, anxiety,
generalized anxiety disorder (GAD), hot flush, post partum
depression, premenstrual syndrome, obesity, obsessive compulsive
disorder, post-traumatic stress disorder, social phobia, disruptive
behavior disorders, impulse control disorders, borderline
personality disorder, chronic fatigue disorder, premature
ejaculation, pain, attention deficit disorders, with and without
hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa, or
Shy Drager Syndrome comprising administration of a selective
serotonin reuptake inhibitor and compound of the formulae I or II:
1 wherein Z is a moiety selected from the group of: 2 wherein:
R.sub.1 is selected from H, OH or the C.sub.1-C.sub.12 esters or
C.sub.1-C.sub.12 alkyl ethers thereof, benzyloxy, or halogen; or
C.sub.1-C.sub.4 halogenated ethers including trifluoromethyl ether
and trichloromethyl ether; R.sub.2, R.sub.3, R.sub.4, R.sub.5, and
R.sub.6 are H, OH or C.sub.1-C.sub.12 esters or C.sub.1-C.sub.12
alkyl ethers thereof, halogens, or C.sub.1-C.sub.4 halogenated
ethers, cyano, C.sub.1-C.sub.6 alkyl, or trifluoromethyl, with the
proviso that, when R.sub.1 is H, R.sub.2 is not OH; Y is the
moiety: 3 R.sub.7 and R.sub.8 are alkyl or concatenated together to
form an optionally substituted, nitrogen-containing ring; or a
pharmaceutically acceptable salt thereof.
Inventors: |
Jenkins, Simon N.; (Audubon,
PA) |
Correspondence
Address: |
Arnold S. Milowsky
American Home Products Corporation
Patent Law Department - 2B
Five Giralda Farms
Madison
NJ
07940
US
|
Assignee: |
American Home Products
Corporation
Five Giralda Farms
Madison
NJ
|
Family ID: |
26910986 |
Appl. No.: |
09/896361 |
Filed: |
June 29, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60216408 |
Jul 6, 2000 |
|
|
|
Current U.S.
Class: |
514/320 ;
514/171; 514/210.21; 514/217.08; 514/414; 514/415 |
Current CPC
Class: |
A61K 31/40 20130101;
A61K 31/55 20130101; A61K 31/404 20130101; A61K 31/40 20130101;
A61K 2300/00 20130101; A61K 2300/00 20130101; A61K 2300/00
20130101; A61K 2300/00 20130101; A61K 2300/00 20130101; A61K 31/135
20130101; A61K 2300/00 20130101; A61K 31/454 20130101; A61K 31/445
20130101; A61K 31/405 20130101; A61K 2300/00 20130101; A61K 31/56
20130101; A61K 45/06 20130101; A61K 31/40 20130101; A61K 31/405
20130101; A61K 31/40 20130101; A61K 31/55 20130101; A61K 31/454
20130101; A61K 31/56 20130101; A61K 31/445 20130101; A61K 31/445
20130101; A61K 31/404 20130101 |
Class at
Publication: |
514/320 ;
514/171; 514/210.21; 514/217.08; 514/414; 514/415 |
International
Class: |
A61K 031/56; A61K
031/454; A61K 031/55; A61K 031/404 |
Claims
What is claimed:
1. A method for treatment of depression, anxiety, generalized
anxiety disorder (GAD), hot flush, post partum depression,
premenstrual syndrome, obesity, obsessive compulsive disorder,
post-traumatic stress disorder, social phobia, disruptive behavior
disorders, impulse control disorders, borderline personality
disorder, chronic fatigue disorder, premature ejaculation, pain,
attention deficit disorders, with and without hyperactivity, Gilles
de la Tourette syndrome, bulimia nervosa, or Shy Drager Syndrome in
a mammal, the method comprising administering to a mammal in need
thereof a pharmaceutically effective amount of a selective
serotonin reuptake inhibitor, or a pharmaceutically acceptable salt
thereof, and a pharmaceutically effective amount of a compound of
the formulae I or II: 19wherein Z is a moiety selected from the
group of: 20wherein: R.sub.1 is selected from H, OH or the
C.sub.1-C.sub.12 esters or C.sub.1-C.sub.12 alkyl ethers thereof,
benzyloxy, or halogen; or C.sub.1-C.sub.4 halogenated ethers
including trifluoromethyl ether and trichloromethyl ether. R.sub.2,
R.sub.3, R.sub.5 and R.sub.6 are independently selected from H, OH
or the C.sub.1-C.sub.12 esters or C.sub.1-C.sub.12 alkyl ethers
thereof, halogens, or C.sub.1-C.sub.4 halogenated ethers, cyano,
C.sub.1-C.sub.6 alkyl, or trifluoromethyl, with the proviso that,
when R.sub.1 is H, R.sub.2 is not OH; R.sub.4 is selected from H,
OH or the C.sub.1-C.sub.12 esters or C.sub.1-C.sub.12 alkyl ethers
thereof, halogens, or C.sub.1-C.sub.4 halogenated ethers,
benzyloxy, cyano, C.sub.1-C.sub.6 alkyl, or trifluoromethyl; X is
selected from H, C.sub.1-C.sub.6 alkyl, cyano, nitro,
trifluoromethyl, halogen; n is 1, 2 or 3; Y is selected from: a)
the moiety: 21wherein R.sub.7 and R.sub.8 are independently
selected from the group of H, C.sub.1-C.sub.6 alkyl, or phenyl
optionally substituted by CN, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkoxy, halogen, --OH, --CF.sub.3, or --OCF.sub.3;
b) a five-membered saturated, unsaturated or partially unsaturated
heterocycle containing up to two heteroatoms selected from the
group consisting of --O--, --NH--, --N(C.sub.1C.sub.4 alkyl)--,
--N.dbd., and --S(O).sub.m--, wherein m is an integer of from 0-2,
optionally substituted with 1-3 substituents independently selected
from the group consisting of hydrogen, hydroxyl, halo,
C.sub.1-C.sub.4 alkyl, trihalomethyl, C.sub.1-C.sub.4 alkoxy,
trihalomethoxy, C.sub.1-C.sub.4 acyloxy, C.sub.1-C.sub.4 alkylthio,
C.sub.1-C.sub.4 alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl,
hydroxy (C.sub.1-C.sub.4)alkyl, --CO.sub.2H--, --CN--,
--CONHR.sub.1--, --NH.sub.2--C.sub.1-C.sub.4 alkylamino,
di(C.sub.1-C.sub.4)alkylamino, --NHSO.sub.2R.sub.1--,
--NHCOR.sub.1--, --NO.sub.2, and phenyl optionally substituted with
1-3 (C.sub.1-C.sub.4)alkyl; c) a six-membered saturated,
unsaturated or partially unsaturated heterocycle containing up to
two heteroatoms selected from the group consisting of --O--,
--NH--, --N(C.sub.1C.sub.4 alkyl)--, --N.dbd., and --S(O).sub.m--,
wherein m is an integer of from 0-2, optionally substituted with
1-3 substituents independently selected from the group consisting
of hydrogen, hydroxyl, halo, C.sub.1-C.sub.4 alkyl, trihalomethyl,
C.sub.1-C.sub.4 alkoxy, trihalomethoxy, C.sub.1-C.sub.4 acyloxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H--, --CN--, --CONHR.sub.1--, --NH.sub.2--,
C.sub.1-C.sub.4 alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2R.sub.1--, --NHCOR.sub.1--, --NO.sub.2, and phenyl
optionally substituted with 1-3 (C.sub.1-C.sub.4)alkyl; d) a
seven-membered saturated, unsaturated or partially unsaturated
heterocycle containing up to two heteroatoms selected from the
group consisting of --O--, --NH--, --N(C.sub.1C.sub.4 alkyl)--,
--N.dbd., and --S(O).sub.m--, wherein m is an integer of from 0-2,
optionally substituted with 1-3 substituents independently selected
from the group consisting of hydrogen, hydroxyl, halo,
C.sub.1-C.sub.4 alkyl, trihalomethyl, C.sub.1-C.sub.4 alkoxy,
trihalomethoxy, C.sub.1-C.sub.4 acyloxy, C.sub.1-C.sub.4 alkylthio,
C.sub.1-C.sub.4 alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl,
hydroxy (C.sub.1-C.sub.4)alkyl, --CO.sub.2H--, --CN--,
--CONHR.sub.1--, --NH.sub.2--, C.sub.1-C.sub.4 alkylamino,
di(C.sub.1-C.sub.4)alkylamino, --NHSO.sub.2R.sub.1--,
--NHCOR.sub.1--, --NO.sub.2, and phenyl optionally substituted with
1-3 (C.sub.1-C.sub.4)alkyl;; or e) a bicyclic heterocycle
containing from 6-12 carbon atoms either bridged or fused and
containing up to two heteroatoms selected from the group consisting
of --O--, --NH--, --N(C.sub.1C.sub.4 alkyl)--, and --S(O).sub.m--,
wherein m is an integer of from 0-2, optionally substituted with
1-3 substituents independently selected from the group consisting
of hydrogen, hydroxyl, halo, C.sub.1-C.sub.4 alkyl, trihalomethyl,
C.sub.1-C.sub.4 alkoxy, trihalomethoxy, C.sub.1-C.sub.4 acyloxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H--, --CN--, --CONHR.sub.1--, --NH.sub.2--,
C.sub.1-C.sub.4 alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2R.sub.1--, --NHCOR.sub.1--, --NO.sub.2, and phenyl
optionally substituted with 1-3 (C.sub.1-C.sub.4) alkyl; or a
pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein in the compound of the formulae I
or II: R.sub.1 is selected from H, OH or the C.sub.1-C.sub.12
esters or alkyl ethers thereof, benzyloxy, or halogen; R.sub.2,
R.sub.3, R.sub.5, and R.sub.6 are independently selected from H, OH
or the C.sub.1-C.sub.12 esters or alkyl ethers thereof, halogen,
cyano, C.sub.1-C.sub.6 alkyl, or trihalomethyl; with the proviso
that, when R.sub.1 is H, R.sub.2 is not OH; R.sub.4 is selected
from H, OH or the C.sub.1-C.sub.12 esters or alkyl ethers thereof,
benzyloxy, halogen, cyano, C.sub.1-C.sub.6 alkyl, or trihalomethyl;
X is selected from H, C.sub.1-C.sub.6 alkyl, cyano, nitro,
trifluoromethyl, halogen; Y is the moiety: 22R.sub.7 and R.sub.8
are selected independently from H, C.sub.1-C.sub.6 alkyl, or
combined by --(CH.sub.2).sub.p--, wherein p is an integer of from 2
to 6, so as to form a ring, the ring being optionally substituted
by up to three substituents selected from the group of hydrogen,
hydroxyl, halo, C.sub.1-C.sub.4 alkyl, trihalomethyl,
C.sub.1-C.sub.4 alkoxy, trihalomethoxy, C.sub.1-C.sub.4 alkylthio,
C.sub.1-C.sub.4 alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl,
hydroxy (C.sub.1-C.sub.4)alkyl, --CO.sub.2H, --CN,
--CONH(C.sub.1-C.sub.4), --NH.sub.3, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino, --NHSO.sub.2(C.sub.1-C.sub.4),
--NHCO(C.sub.1-C.sub.4), and --NO.sub.3; or a pharmaceutically
acceptable salt thereof.
3. The method of claim 2 wherein, in the compound of the formulae I
or II, the ring formed by a the combination of R.sub.7 and R.sub.8
by --(CH.sub.2).sub.p-- is selected from aziridine, azetidine,
pyrrolidine, piperidine, hexamethyleneamine or
heptamethyleneamine.
4. The method of claim 1 utilizing a compound of the formulae I or
II, wherein R.sub.1 is OH; R.sub.2-R.sub.6 are as defined in claim
1; X is selected from the group of Cl, NO.sub.2, CN, CF.sub.3, or
CH.sub.3; and Y is the moiety: 23and R.sub.7 and R.sub.8 are
concatenated together as --(CH.sub.2).sub.r--, wherein r is an
integer of from 4 to 6, to form a ring optionally substituted by up
to three substituents selected from the group of hydrogen,
hydroxyl, halo, C.sub.1-C.sub.4 alkyl, trihalomethyl,
C.sub.1-C.sub.4 alkoxy, trihalomethoxy, C.sub.1-C.sub.4 alkylthio,
C.sub.1-C.sub.4 alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl,
hydroxy (C.sub.1-C.sub.4)alkyl, --CO.sub.2H, --CN,
--CONH(C.sub.1-C.sub.4)alkyl, --NH.sub.2, C.sub.1-C.sub.4
alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2(C.sub.1-C.sub.4)alkyl, --NHCO(C.sub.1-C.sub.4)alkyl,
and --NO.sub.2; or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 wherein the SSRI is selected from the
group of venlafaxine, fluoxetine, paroxetine, sertraline, or
fluvoxamine, or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 wherein the disorder is depression.
7. The method of claim 1 wherein the disorder is pain.
8. The method of claim 1 wherein the disorder is generalized
anxiety disorder.
9. The method of claim 1 wherein the disorder is anxiety.
10. A method for treating depression, anxiety, generalized anxiety
disorder (GAD), hot flush, post partum depression, premenstrual
syndrome, obesity, obsessive compulsive disorder, post-traumatic
stress disorder, social phobia, disruptive behavior disorders,
impulse control disorders, borderline personality disorder, chronic
fatigue disorder, premature ejaculation, pain, attention deficit
disorders, with and without hyperactivity, Gilles de la Tourette
syndrome, bulimia nervosa, or Shy Drager Syndrome in a mammal, the
method comprising administering to a mammal in need thereof a
pharmaceutically effective amount of a SSRI, or a pharmaceutically
acceptable salt thereof, and a pharmaceutically effective amount of
a compound of the formulae I or II: 24wherein R.sub.1, R.sub.2,
R.sub.3, R.sub.4, R.sub.5, R.sub.6, n, X, and Y are as defined in
claim 1, or a pharmaceutically acceptable salt thereof.
11. A method for treating depression, anxiety, generalized anxiety
disorder (GAD), hot flush, post partum depression, premenstrual
syndrome, obesity, obsessive compulsive disorder, post-traumatic
stress disorder, social phobia, disruptive behavior disorders,
impulse control disorders, borderline personality disorder, chronic
fatigue disorder, premature ejaculation, pain, attention deficit
disorders, with and without hyperactivity, Gilles de la Tourette
syndrome, bulimia nervosa, or Shy Drager Syndrome in a mammal, the
method comprising administering to a mammal in need thereof a
pharmaceutically effective amount of a SSRI, or a pharmaceutically
acceptable salt thereof, and a pharmaceutically effective amount of
a compound of the formulae (V) or (VI): 25wherein R.sub.1, R.sub.2,
R.sub.3, R.sub.4, R.sub.5, R.sub.6, X, and Y are as defined in
claim 1, or a pharmaceutically acceptable salt thereof.
12. A method for treating depression, anxiety, generalized anxiety
disorder (GAD), hot flush, post partum depression, premenstrual
syndrome, obesity, obsessive compulsive disorder, post-traumatic
stress disorder, social phobia, disruptive behavior disorders,
impulse control disorders, borderline personality disorder, chronic
fatigue disorder, premature ejaculation, pain, attention deficit
disorders, with and without hyperactivity, Gilles de la Tourette
syndrome, bulimia nervosa, or Shy Drager Syndrome in a mammal, the
method comprising administering to a mammal in need thereof a
pharmaceutically effective amount of a SSRI, or a pharmaceutically
acceptable salt thereof, and a pharmaceutically effective amount of
a compound of the formulae VII and VIII: 26wherein R.sub.1,
R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, n, X, and Y are as
defined in claim 1, or a pharmaceutically acceptable salt
thereof.
13. A method for treating depression, anxiety, generalized anxiety
disorder (GAD), hot flush, post partum depression, premenstrual
syndrome, obesity, obsessive compulsive disorder, post-traumatic
stress disorder, social phobia, disruptive behavior disorders,
impulse control disorders, borderline personality disorder, chronic
fatigue disorder, premature ejaculation, pain, attention deficit
disorders, with and without hyperactivity, Gilles de la Tourette
syndrome, bulimia nervosa, or Shy Drager Syndrome in a mammal, the
method comprising administering to a mammal in need thereof a
pharmaceutically effective amount of 1-[4-(2-Azepan-1
yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indo- l-5-ol
and a pharmaceutically effective amount of a SSRI, or a
pharmaceutically acceptable salt thereof.
14. The method of claim 14 wherein the SSRI is selected from the
group of venlafaxine, fluoxetine, paroxetine, sertraline, or
fluvoxamine, or a pharmaceutically acceptable salt thereof.
15. A method for treating depression, anxiety, generalized anxiety
disorder (GAD), hot flush, post partum depression, premenstrual
syndrome, obesity, obsessive compulsive disorder, post-traumatic
stress disorder, social phobia, disruptive behavior disorders,
impulse control disorders, borderline personality disorder, chronic
fatigue disorder, premature ejaculation, pain, attention deficit
disorders, with and without hyperactivity, Gilles de la Tourette
syndrome, bulimia nervosa, or Shy Drager Syndrome in a mammal, the
method comprising administering to a mammal in need thereof a
pharmaceutically effective amount of
2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-i-
ndol-5-ol and a pharmaceutically effective amount of a SSRI, or a
pharmaceutically acceptable salt thereof.
16. The method of claim 16 wherein the SSRI is selected from the
group of venlafaxine, fluoxetine, paroxetine, sertraline, or
fluvoxamine, or a pharmaceutically acceptable salt thereof.
Description
[0001] This application claims the benefit of U.S. Provisional
Application No. 60/216,408, filed Jul. 6, 2000.
[0002] This invention relates to methods of using substituted
indole compounds in the combination with a selective serotonin
reuptake inhibitor (SSRI) for the treatment, prevention, inhibition
or alleviation of depression, anxiety, generalized anxiety disorder
(GAD), hot flush, post partum depression, premenstrual syndrome,
obesity, obsessive compulsive disorder, social phobia, disruptive
behavior disorders, impulse control disorders, borderline
personality disorder, chronic fatigue disorder, premature
ejaculation, pain, post-traumatic stress disorder, attention
deficit disorders, with and without hyperactivity, Gilles de la
Tourette syndrome, bulimia nervosa, or Shy Drager Syndrome and
related pharmaceutical compositions and kits.
BACKGROUND OF THE INVENTION
[0003] EP 0 802 183 A1 and U.S. Pat. No. 5,780,497 describe
substituted indole compounds of the formulae below: 4
[0004] as well as their use as estrogenic agents, including the
treatment of bone loss, cardiovascular disease, maladies associated
with or resulting from the proliferation or abnormal development of
endometrial or endometrial-like tissues, and disease states or
syndromes associated with estrogen deficiency.
[0005] EP 0 802 184 A1, published Oct. 22, 1997, describes
comparable uses for substituted indole compounds of the formulae
below. 5
[0006] Analogous indole compounds having the general structures:
6
[0007] are described in U.S. Pat. No. 5,880,137 (Miller et
al.).
[0008] Filipponi P et al: Cyclical clodronate is effective in
preventing postmenopausal bone loss: A comparative study with
transcutaneous hormone replacement therapy. J Bone Min Res
10:697-703, 1995.
[0009] DESCRIPTION OF THE INVENTION
[0010] This invention comprises methods of treating, preventing,
alleviating or inhibiting depression, anxiety, generalized anxiety
disorder (GAD), hot flush, post partum depression, premenstrual
syndrome, obesity, obsessive compulsive disorder, post-traumatic
stress disorder, social phobia, disruptive behavior disorders,
impulse control disorders, borderline personality disorder, chronic
fatigue disorder, premature ejaculation, pain, attention deficit
disorders, with and without hyperactivity, Gilles de la Tourette
syndrome, bulimia nervosa, or Shy Drager Syndrome in a mammal,
preferably in a human, the methods comprising administering to a
mammal in need thereof a pharmaceutically effective combination
of:
[0011] a) a pharmaceutically effective amount of a selective
serotonin reuptake inhibitor (SSRI), or a pharmaceutically
effective salt thereof; and
[0012] b) a pharmaceutically effective amount of a substituted
indole compound of the formulae I or II, below: 7
[0013] wherein Z is a moiety selected from the group of: 8
[0014] wherein:
[0015] R.sub.1 is selected from H, OH or the C.sub.1-C.sub.12
esters (straight chain or branched) or C.sub.1-C.sub.12 (straight
chain or branched or cyclic) alkyl ethers thereof, benzyloxy, or
halogens; or C.sub.1-C.sub.4 halogenated ethers including
trifluoromethyl ether and trichloromethyl ether.
[0016] R.sub.2, R.sub.3, R.sub.5, and R.sub.6 are independently
selected from H, OH or the C.sub.1-C.sub.12 esters (straight chain
or branched) or C.sub.1-C.sub.12 alkyl ethers (straight chain or
branched or cyclic) thereof, halogens, or C.sub.1-C.sub.4
halogenated ethers including trifluoromethyl ether and
trichloromethyl ether, cyano, C.sub.1-C.sub.6 alkyl (straight chain
or branched), or trifluoromethyl, with the proviso that, when
R.sub.1 is H, R.sub.2 is not OH;
[0017] R.sub.4 is selected from H, OH or the C.sub.1-C.sub.12
esters (straight chain or branched) or C.sub.1-C.sub.12 alkyl
ethers (straight chain or branched or cyclic) thereof, benzyloxy,
halogens, or C.sub.1-C.sub.4 halogenated ethers including
trifluoromethyl ether and trichloromethyl ether, cyano,
C.sub.1-C.sub.6 alkyl (straight chain or branched), or
trifluoromethyl;
[0018] X is selected from H, C.sub.1-C.sub.6 alkyl, cyano, nitro,
trifluoromethyl, halogen;
[0019] n is 1, 2 or 3;
[0020] Y is selected from:
[0021] a) the moiety: 9
[0022] wherein R.sub.7 and R.sub.8 are independently selected from
the group of H, C.sub.1-C.sub.6 alkyl, or phenyl optionally
substituted by CN, C.sub.1-C.sub.6 alkyl (straight chain or
branched), C.sub.1-C.sub.6 alkoxy (straight chain or branched),
halogen, --OH, --CF.sub.3, or --OCF.sub.3;
[0023] b) a five-membered saturated, unsaturated or partially
unsaturated heterocycle containing up to two heteroatoms selected
from the group consisting of --O--, --NH--, --N(C.sub.1C.sub.4
alkyl)-, --N.dbd., and --S(O).sub.m--, wherein m is an integer of
from 0-2, optionally substituted with 1-3 substituents
independently selected from the group consisting of hydrogen,
hydroxyl, halo, C.sub.1-C.sub.4 alkyl, trihalomethyl,
C.sub.1-C.sub.4 alkoxy, trihalomethoxy, C.sub.1-C.sub.4 acyloxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H--, --CN--, --CONHR.sub.1--, --NH.sub.2--,
C.sub.1-C.sub.4 alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2R.sub.1--, --NHCOR.sub.1--, --NO.sub.2, and phenyl
optionally substituted with 1-3 (C.sub.1-C.sub.4)alkyl;
[0024] c) a six-membered saturated, unsaturated or partially
unsaturated heterocycle containing up to two heteroatoms selected
from the group consisting of --O--, --NH--, --N(C.sub.1C.sub.4
alkyl)-, --N.dbd., and --S(O).sub.m--, wherein m is an integer of
from 0-2, optionally substituted with 1-3 substituents
independently selected from the group consisting of hydrogen,
hydroxyl, halo, C.sub.1-C.sub.4 alkyl, trihalomethyl,
C.sub.1-C.sub.4 alkoxy, trihalomethoxy, C.sub.1-C.sub.4 acyloxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H--, --CN--, --CONHR.sub.1--, --NH.sub.2--,
C.sub.1-C.sub.4 alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2R.sub.1--, --NHCOR.sub.1--, --NO.sub.2, and phenyl
optionally substituted with 1-3 (C.sub.1-C.sub.4)alkyl;
[0025] d) a seven-membered saturated, unsaturated or partially
unsaturated heterocycle containing up to two heteroatoms selected
from the group consisting of --O--, --NH--, --N(C.sub.1C.sub.4
alkyl)-, --N.dbd., and --S(O).sub.m--, wherein m is an integer of
from 0-2, optionally substituted with 1-3 substituents
independently selected from the group consisting of hydrogen,
hydroxyl, halo, C.sub.1-C.sub.4 alkyl, trihalomethyl,
C.sub.1-C.sub.4 alkoxy, trihalomethoxy, C.sub.1-C.sub.4 acyloxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H--, --CN--, --CONHR.sub.1--, --NH.sub.2--,
C.sub.1-C.sub.4 alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2R.sub.1--, --NHCOR.sub.1--, --NO.sub.2, and phenyl
optionally substituted with 1-3 (C.sub.1-C.sub.4)alkyl; or
[0026] e) a bicyclic heterocycle containing from 6-12 carbon atoms
either bridged or fused and containing up to two heteroatoms
selected from the group consisting of --O--, --NH--,
--N(C.sub.1C.sub.4 alkyl)-, and --S(O).sub.m--, wherein m is an
integer of from 0-2, optionally substituted with 1-3 substituents
independently selected from the group consisting of hydrogen,
hydroxyl, halo, C.sub.1-C.sub.4 alkyl, trihalomethyl,
C.sub.1-C.sub.4 alkoxy, trihalomethoxy, C.sub.1-C.sub.4 acyloxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H--, --CN--, --CONHR.sub.1--, --NH.sub.2--,
C.sub.1-C.sub.4 alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2R.sub.1--, --NHCOR.sub.1--, --NO.sub.2, and phenyl
optionally substituted with 1-3 (C.sub.1-C.sub.4) alkyl;
[0027] and the pharmaceutically acceptable salts thereof.
[0028] The more preferred substituted indole compounds of this
invention are those having the general structures I or II, above,
wherein:
[0029] R.sub.1 is selected from H, OH or the C.sub.1-C.sub.12
esters or alkyl ethers thereof, benzyloxy, or halogen;
[0030] R.sub.2, R.sub.3, R.sub.5, and R.sub.6 are independently
selected from H, OH or the C.sub.1-C.sub.12 esters or alkyl ethers
thereof, halogen, cyano, C.sub.1-C.sub.6 alkyl, or trihalomethyl,
preferably trifluoromethyl, with the proviso that, when R.sub.1 is
H, R.sub.2 is not OH;
[0031] R.sub.4 is selected from H, OH or the C.sub.1-C.sub.12
esters or alkyl ethers thereof, benzyloxy, halogen, cyano,
C.sub.1-C.sub.6 alkyl, or trihalomethyl;
[0032] X is selected from H, C.sub.1-C.sub.6 alkyl, cyano, nitro,
trifluoromethyl, halogen;
[0033] Y is the moiety 10
[0034] R.sub.7 and R.sub.8 are selected independently from H,
C.sub.1-C.sub.6 alkyl, or combined by --(CH.sub.2).sub.p--, wherein
p is an integer of from 2 to 6, so as to form a ring, the ring
being optionally substituted by up to three substituents selected
from the group of hydrogen, hydroxyl, halo, C.sub.1-C.sub.4 alkyl,
trihalomethyl, C.sub.1-C.sub.4 alkoxy, trihalomethoxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H, --CN, --CONH(C.sub.1-C.sub.4), --NH.sub.3,
C.sub.1-C.sub.4 alkylamino, C.sub.1-C.sub.4 dialkylamino,
--NHSO.sub.2(C.sub.1-C.sub.4), --NHCO(C.sub.1-C.sub.4), and
--NO.sub.3;
[0035] and the pharmaceutically acceptable salts thereof.
[0036] The rings formed by a concatenated R.sub.7 and R.sub.8,
mentioned above, may include, but are not limited to, aziridine,
azetidine, pyrrolidine, piperidine, hexamethyleneamine or
heptamethyleneamine rings.
[0037] The most preferred substituted indole compounds of the
present invention are those having the structural formulas I or II,
above, wherein R.sub.1 is OH; R.sub.2-R.sub.6 are as defined above;
X is selected from the group of Cl, NO.sub.2, CN, CF.sub.3, or
CH.sub.3; and Y is the moiety 11
[0038] and R.sub.7 and R.sub.8 are concatenated together as
--(CH.sub.2).sub.r--, wherein r is an integer of from 4 to 6, to
form a ring optionally substituted by up to three substituents
selected from the group of hydrogen, hydroxyl, halo,
C.sub.1-C.sub.4 alkyl, trihalomethyl, C.sub.1-C.sub.4 alkoxy,
trihalomethoxy, C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4
alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl, hydroxy
(C.sub.1-C.sub.4)alkyl, --CO.sub.2H, --CN,
--CONH(C.sub.1-C.sub.4)alkyl, --NH.sub.2, C.sub.1-C.sub.4
alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2(C.sub.1-C.sub.4)alkyl, --NHCO(C.sub.1-C.sub.4)alkyl,
and --NO.sub.2;
[0039] and the pharmaceutically acceptable salts thereof.
[0040] In another embodiment of this invention, when R.sub.7 and
R.sub.8 are concatenated together as --(CH.sub.2).sub.p--, wherein
p is an integer of from 2 to 6, preferably 4 to 6, the ring so
formed is optionally substituted with 1-3 substituents selected
from a group containing C.sub.1-C.sub.3 alkyl, trifluoromethyl,
halogen, hydrogen, phenyl, nitro, --CN.
[0041] The invention includes sulfate, sulfamates and sulfate
esters of phenolic groups of the substituted indoles. Sulfates can
be readily prepared by the reaction of the free phenolic compounds
with sulfur trioxide complexed with an amine such as pyridine,
trimethylamine, triethylamine, etc. Sulfamates can be prepared by
treating the free phenolic compound with the desired amino or
alkylamino or dialkylamino sulfamyl chloride in the presence of a
suitable base such as pyridine. Sulfate esters can be prepared by
reaction of the free phenol with the desired alkanesulfonyl
chloride in the presence of a suitable base such as pyridine.
Additionally, this invention includes compounds containing
phosphates at the phenol as well as dialkyl phosphates. Phosphates
can be prepared by reaction of the phenol with the appropriate
chlorophosphate. The dialkylphosphates can be hydrolyzed to yield
the free phosphates. Phosphinates are also claimed where the phenol
is reacted with the desired dialkylphosphinic chloride to yield the
desired dialkylphosphinate of the phenol.
[0042] The invention includes acceptable salt forms of the
substituted indole formed from the addition reaction with either
inorganic or organic acids. Inorganic acids such as hydrochloric
acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric
acid, nitric acid useful as well as organic acids such as acetic
acid, propionic acid, citric acid, maleic acid, malic acid,
tartaric acid, phthalic acid, succinic acid, methanesulfonic acid,
toluenesulfonic acid, napthalenesulfonic acid, camphorsulfonic
acid, benzenesulfonic acid are useful. It is known that compounds
possessing a basic nitrogen can be complexed with many different
acids (both protic and non-protic) and usually it is preferred to
administer a compound of this invention in the form of an acid
addition salt. Additionally, this invention includes quaternary
ammonium salts of the compounds herein. These can be prepared by
reacting the nucleophilic amines of the side chain with a suitably
reactive alkylating agent such as an alkyl halide or benzyl
halide.
[0043] The present invention includes methods for treating pain
using the combinations described herein. Pain in these instances
includes, but is not limited to, neuropathic pain, chronic pain,
musculoskeletal pain, cancer pains, fibromyalgia, psychogenic pain,
neurogenic pain, facial neuralgias and pain associated with
shingles.
[0044] These methods each comprise administering to a mammal in
need thereof a pharmaceutically effective amount of a SSRI agent
and a pharmaceutically effective amount of one of the substituted
indoles taught herein, or a pharmaceutically acceptable salt of
either of these agents. These administrations may be therapeutic or
prophylactic. Among the preferred substituted indole compounds for
use in these methods are
1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-
-5-ol, also known as TSE-424, and
2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-pi-
peridin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol, also known as
ERA-923.
[0045] SSRI agents useful with the present methods of treatment
include, but are not limited to, venlafaxine, fluoxetine,
paroxetine, sertraline, or fluvoxamine, or a pharmaceutically
acceptable salt thereof.
[0046] The present invention includes methods utilizing in
conjunction with a SSRI compound a first subset or subgroup of
substituted indole compounds of the formulas III or IV, below:
12
[0047] wherein the variable substituents including R.sub.1,
R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, n, X, and Y are as
defined above, or a pharmaceutically acceptable salt thereof.
[0048] The more preferred substituted indole compounds of this
first subset of compounds are those having the general structures
III or IV, above, wherein:
[0049] R.sub.1 is selected from H, OH or the C.sub.1-C.sub.12
esters or alkyl ethers thereof, benzyloxy, or halogen;
[0050] R.sub.2, R.sub.3, R.sub.5, and R.sub.6 are independently
selected from H, OH or the C.sub.1-C.sub.12 esters or alkyl ethers
thereof, halogen, cyano, C.sub.1-C.sub.6 alkyl, or trihalomethyl,
preferably trifluoromethyl, with the proviso that, when R.sub.1 is
H, R.sub.2 is not OH;
[0051] R.sub.4 is selected from H, OH or the C.sub.1-C.sub.12
esters or alkyl ethers thereof, benzyloxy, halogen, cyano,
C.sub.1-C.sub.6 alkyl, or trihalomethyl;
[0052] X is selected from H, C.sub.1-C.sub.6 alkyl, cyano, nitro,
trifluoromethyl, halogen;
[0053] Y is the moiety 13
[0054] R.sub.7 and R.sub.8 are selected independently from H,
C.sub.1-C.sub.6 alkyl, or combined by --(CH.sub.2).sub.p--, wherein
p is an integer of from 2 to 6, so as to form a ring, the ring
being optionally substituted by up to three substituents selected
from the group of hydrogen, hydroxyl, halo, C.sub.1-C.sub.4 alkyl,
trihalomethyl, C.sub.1-C.sub.4 alkoxy, trihalomethoxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H, --CN, --CONH(C.sub.1-C.sub.4), --NH.sub.3,
C.sub.1-C.sub.4 alkylamino, C.sub.1-C.sub.4 dialkylamino,
--NHSO.sub.2(C.sub.1-C.sub.4), --NHCO(C.sub.1-C.sub.4), and
--NO.sub.3; and the pharmaceutically acceptable salts thereof.
[0055] The rings formed by a concatenated R.sub.7 and R.sub.8,
mentioned above, may include, but are not limited to, aziridine,
azetidine, pyrrolidine, piperidine, hexamethyleneamine or
heptamethyleneamine rings.
[0056] The most preferred substituted indole compounds of this
first subset of compounds are those having the structural formulas
I or II, above, wherein R.sub.1 is OH; R.sub.2-R.sub.6 are as
defined above; X is selected from the group of Cl, NO.sub.2, CN,
CF.sub.3, or C.sub.3; and Y is the moiety 14
[0057] and R.sub.7 and R.sub.8 are concatenated together as
--(CH.sub.2).sub.r, wherein r is an integer of from 4 to 6, to form
a ring optionally substituted by up to three substituents selected
from the group of hydrogen, hydroxyl, halo, C.sub.1-C.sub.4 alkyl,
trihalomethyl, C.sub.1-C.sub.4 alkoxy, trihalomethoxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H, --CN, --CONH(C.sub.1-C.sub.4)alkyl, --NH.sub.2,
C.sub.1-C.sub.4 alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2(C.sub.1-C.sub.4)alkyl, --NHCO(C.sub.1-C.sub.4)alkyl,
and --NO.sub.2;
[0058] and the pharmaceutically acceptable salts thereof.
[0059] In another embodiment of this first subset of compounds,
when R.sub.7 and R.sub.8 are concatenated together as
--(CH.sub.2).sub.p--, wherein p is an integer of from 2 to 6,
preferably 4 to 6, the ring so formed is optionally substituted
with 1-3 substituents selected from a group containing
C.sub.1-C.sub.3 alkyl, trifluoromethyl, halogen, hydrogen, phenyl,
nitro, --CN.
[0060] Among the preferred compounds of this first subset of
substituted indoles are the following:
[0061]
5-Benzyloxy-2-(4-ethoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-eth-
oxy)-benzyl]-1H-indole;
[0062]
5-Benzyloxy-2-phenyl-3-methyl-1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-1-
H-indole;
[0063]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-azepan-1-yl-eth-
oxy)-benzyl]-1H-indole;
[0064]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-diisopropylamin-
o-1-yl-ethoxy)-benzyl]-l H-indole;
[0065]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-butyl-methylami-
no-1-ylethoxy)-benzyl]-1H-indole;
[0066]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-dimethylamino)-eth-
oxy]-benzyl}-1H-indole;
[0067]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-(2-methyl-piper-
idin-1-yl)-ethoxy]-benzyl}-1H-indole;
[0068]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-(3-methyl-piper-
idin-1-yl)-ethoxy]-benzyl}-1H-indole;
[0069]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-(4-methyl-piper-
idin-1-yl)-ethoxy]-benzyl}-1H-indole;
[0070]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1{4-[2-((cis)-2,6-Dimet-
hyl-piperidin-1-yl)-ethoxy]-benzyl}-1H-indole;
[0071]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-{4-[2-(1,3,3-trimethyl--
6-aza-bicyclo[3.2.1 ]oct-6-yl)-ethoxy]-benzyl}-1H-indole;
[0072]
(1S,4R)-5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl{4-[2-(2-Aza-bic-
yclo [2.2.1] hept-2-yl)-ethoxy]-benzyl}-1H-indole;
[0073]
5-Benzyloxy-2-(4-flouro-phenyl)-3-methyl-1-[4-(2-azepan-1-yl-ethoxy-
)-benzyl]-1H-indole;
[0074]
5-Benzyloxy-2-(4-flouro-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-eth-
oxy)-benzyl]-1H-indole;
[0075]
5-Benzyloxy-2-(4-chloro-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-eth-
oxy)-benzyl]-1H-indole;
[0076]
5-Benzyloxy-2-[3,4-methylenedioxy-phenyl]-3-methyl-1-[4-(2-piperidi-
n-1-yl-ethoxy)-benzyl]-1H-indole;
[0077]
5-Benzyloxy-2-[4-isopropoxy-phenyl]-3-methyl-1-[4-(2-piperidin-1-yl-
-ethoxy)-benzyl]-1H-indole;
[0078]
5-Benzyloxy-2-[4-methyl-phenyl]-3-methyl-1-[4-(2-piperidin-1-yl-eth-
oxy)-benzyl]-1H-indole;
[0079]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-benzyloxy-2-(3-benzyloxy-phen-
yl)-3-methyl-1H-indole;
[0080]
5-Benzyloxy-2-(4-benzyloxy-3-fluoro-phenyl)-3-methyl-1-[4-(2-piperi-
din-1-yl-ethoxy)-benzyl]-1H-indole;
[0081]
5-Benzyloxy-2-(4-benzyloxy-3-fluoro-phenyl)-3-methyl-1-[4-(2-azepan-
-1-yl-ethoxy)-benzyl]-1H-indole;
[0082]
5-Benzyloxy-2-(3-methoxy-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-benz-
yl]-3-methyl-1H-indole;
[0083]
5-Benzyloxy-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-(4-tr-
ifluoromethoxy-phenyl)-1H-indole;
[0084]
(2-{4-[5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-indol-1-ylmethyl-
]-phenoxy}-ethyl)-cyclohexyl-amine;
[0085]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-methylpiperazin-1--
yl)-ethoxy]-benzyl}-1H-indole;
[0086]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-benzyloxy-2-(3-methoxy-phenyl-
)-3-methyl-1H-indole;
[0087]
4-{3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indole};
[0088]
4-{3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-2-yl}-p-
henol;
[0089]
3-Methyl-2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)-benzyl]-1H-indol--
5-ol;
[0090]
4-{5-Methoxy-3-methyl-1-{4-[2-(piperidin-1-yl)-ethoxy]-benzyl}-1H-i-
ndol-2-yl}-phenol;
[0091]
2-(4-methoxy-phenyl)-3-methyl-1-{4-[2-(piperidin-1-yl)-ethoxy]-benz-
yl}-1H-indol-5-ol;
[0092]
5-Methoxy-2-(4-methoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-etho-
xy)-benzyl]-1H-indole;
[0093]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-methoxy-2-(4-methoxy-phenyl)--
3-methyl-1H-indole;
[0094]
2-(4-Ethoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-
-1H-indol-5-ol;
[0095]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-ethoxy-phenyl)-3-methyl-1H-
-indol-5-ol;
[0096]
4-{5-Fluoro-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indo-
l-2-yl}-phenol;
[0097]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-3-methyl-2-phenyl-1H-indol-5-ol-
;
[0098]
2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-pyrollidin-1-yl-ethoxy)-benzy-
l]-1H-indol-5-ol;
[0099]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1-
H-indol-5-ol;
[0100]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1-
H-indol-5-ol;
[0101]
1-[4-(2-Azocan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1-
H-indol-5-ol;
[0102]
2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-dimethyl-1-yl-ethoxy)-benzyl]-
-1H-indol-5-ol;
[0103]
2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-diethyl-1-yl-ethoxy)-benzyl]--
1H-indol-5-ol;
[0104]
1-[4-(2-Dipropylamino-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-
-1H-indol-5-ol;
[0105]
1-[4-(2-Dibutylamino-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl--
1H-indol-5-ol;
[0106]
1-[4-(2-Diisopropylamino-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-met-
hyl-1H-indol-5-ol;
[0107]
1-{4-[2-(Butyl-methyl-amino)-ethoxy]-benzyl}-2-(4-hydroxy-phenyl)-3-
-methyl-H-indol-5-ol;
[0108]
2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(2-methyl-piperidin-1-yl)-eth-
oxy]-benzyl}-1H-indol-5-ol;
[0109]
2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(3-methyl-piperdin-1-yl)-etho-
xy]-benzyl}-1H-indol-5-ol;
[0110]
2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(4-methyl-piperidin-1-yl)-eth-
oxy]-benzyl}-1H-indol-5-ol;
[0111]
1-{4-[2-(3,3-Dimethyl-piperidin-1-yl)-ethoxy]-benzyl}-2-(4-hydroxy--
phenyl)-3-methyl-1H-indol-5-ol;
[0112]
1-{4-[2-((cis)-2,6-Dimethyl-piperidin-1-yl)-ethoxy]-benzyl}-2-(4-hy-
droxy-phenyl)-3-methyl-1H-indol-5-ol;
[0113]
2-(4-Hydroxy-phenyl)-1-{4-[2-(4-hydroxy-piperidin-1-yl)-ethoxy]-ben-
zyl}-3-methyl-1H-indol-5-ol;
[0114] (1S,4R)-1-{4-[2-(2-Aza-bicyclo [2.2.1]
hept-2-yl)-ethoxy]-benzyl}-2-
-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol;
[0115]
2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(1,3,3-trimethyl-6-aza-bicycl-
o[3.2.1 ]oct-6-yl)-ethoxy]-benzyl}-1H-indol-5-ol;
[0116]
2-(4-Fluoro-phenyl)-3-methyl-1-[4-(2-piperidine-1-yl-ethoxy)-benzyl-
]-1H-indol-5-ol;
[0117]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-fluoro-phenyl)-3-methyl-1H-
-indol-5-ol;
[0118]
2-(3-Methoxy-4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-etho-
xy)-benzyl]-1H-indol-5-ol;
[0119]
2-Benzo[1,3]dioxol-5-yl-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-ben-
zyl]-1H-indol-5-ol;
[0120]
2-(4-Isopropoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-ben-
zyl]-1H-indol-5-ol;
[0121]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-isopropoxy-phenyl)-3-methy-
l-1H-indol-5-ol;
[0122]
2-(4-Cyclopenyloxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)--
benzyl]-1H-indol-5-ol;
[0123]
3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-(4-trifluoromethy-
l-phenyl)-1H-indol-5-ol;
[0124]
3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-p-tolyl-1H-indol--
5-ol;
[0125]
2-(4-Chloro-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-
-1H-indol-5-ol;
[0126]
2-(2,4-Dimethoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-be-
nzyl]-1H-indol-5-ol;
[0127]
2-(3-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl-
]-1H-indol-5-ol;
[0128]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(3-hydroxy-phenyl)-3-methyl-1-
H-indole-5-ol;
[0129]
2-(3-Fluoro-4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethox-
y)-benzyl]-1H-indol-5-ol;
[0130]
2-(3-Fluoro-4-hydroxy-phenyl)-3-methyl-1-[4-(azepan-1-yl-ethoxy)-be-
nzyl]-1H-indol-5-ol;
[0131]
2-(3-Methoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl-
]-1H-indole-5-ol;
[0132]
3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-(4-trifluorometho-
xy-phenyl)-1H-indole-5-ol;
[0133]
3-Chloro-2-(4-hydroxy-phenyl)-1-[4-(2-pyrrolidin-1-yl-ethoxy)-benzy-
l]-1H-indol-5-ol;
[0134]
3-Chloro-2-(4-hydroxy-phenyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl-
]-1H-indol-5-ol;
[0135]
3-Chloro-2-(4-hydroxy-phenyl)-1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-1-
H-indol-5-ol;
[0136]
3-Chloro-2-(4-hydroxy-2-methyl-phenyl)-1-[4-(2-piperidin-1-yl-ethox-
y)-benzyl]-1H-indol-5-ol;
[0137]
2-(4-Hydroxy-phenyl)-3-ethyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl--
1H-indol-5-ol;
[0138]
5-Hydroxy-2-(4-Hydroxy-phenyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benzy-
l]-1H-indole-3-carbonitrile;
[0139]
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-hydroxy-2-(4-hydroxy-phenyl)--
1H-indole-3-cabonitrile;
[0140]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-chloro-1-[4-(2-piperidin-1-yl--
ethoxy)-benzyl]-1H-indole;
[0141]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-chloro-1-[4-(2-azepan-1-yl-eth-
oxy)-benzyl]-1H-indole;
[0142]
5-Benzyloxy-2-(2-methyl-4-benzyloxy-phenyl)-3-chloro-1-[4-(2-piperi-
din-1-yl-ethoxy)-benzyl]-1H-indole;
[0143]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-ethyl-1-[4-(2-piperidin-1-yl-e-
thoxy)-benzyl]-1H-indole;
[0144]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-cyano-1-[4-(2-piperidin-1-yl-e-
thoxy)-benzyl]-1H-indole;
[0145]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-cyano-1-[4-(2-azepan-1-yl-etho-
xy)-benzyl]-1H-indole;
[0146] Di-propionate of
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-p-
henyl)-3-methyl-1H-indol-5-ol;
[0147] Di-pivalate of
1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phe-
nyl)-3-methyl-1H-indol-5-ol;
[0148]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-1-[4-(3-piperidin-1-yl-propoxy)--
benzyl]-3-methyl-1H-indole;
[0149]
2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[3-(piperidin-1-yl)-propoxy]-ben-
zyl}-1H-indol-5-ol;
[0150]
2-(4-Hydroxy-phenyl)-1-[3-methoxy-4-(2-piperidin-1-yl-ethoxy)-benzy-
l]-3-methyl-1H-indol-5-ol;
[0151]
2-(4-Hydroxy-phenyl)-1-[3-methoxy-4-(2-azepan-1-yl-ethoxy)-benzyl]--
3-methyl-1H-indol-5-ol;
[0152]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[3-Methoxy-4-(2-piper-
idin-1-yl-ethoxy)-benzyl]-1H-indole;
[0153]
5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[2-Methoxy-4-(2-azepa-
n-1-yl-ethoxy)-benzyl]-1H-indole;
[0154]
2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl-
]-1H-indol-5-ol;
[0155] or the pharmaceutically acceptable salts thereof.
[0156] The compounds of this first subset or subgroup of compounds
can be produced by the methods described in EP 0 802 183 A1,
published Oct. 22, 1997, and U.S. Pat. No. 5,780,497, the subject
matter of which is incorporated herein by reference, or by other
methods known in the art. Aryloxy-alkyl-dialkylamines or
aryloxy-alkyl-cyclic amines useful as intermediates in the
production of the compounds above can be produced and used as
disclosed in WO 99/19293, published Apr. 22, 1999, the subject
matter of which is also incorporated herein by reference.
[0157] A second subset or subgroup of substituted indole compounds
useful with this invention includes those of formulas (V) or (VI),
below: 15
[0158] wherein the variable substituents including R.sub.1,
R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, n, X, and Y are as
defined above, or a pharmaceutically acceptable salt thereof.
[0159] Among the preferred substituted indole compounds of this
second subset or subgroup are the following:
[0160]
(E)-N,N-Diethyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-
-1-ylmethyl]-phenyl}-acrylamide;
[0161] 1
(E)-N-tert-butyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-in-
dol-1-ylmethyl]-phenyl}-acrylamide;
[0162]
(E)-Pyrollidino-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-
-1-ylmethyl]-phenyl}-acrylamide;
[0163]
(E)-N,N-Dimethyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indo-
l-1-ylmethyl]-phenyl}-acrylamide;
[0164]
(E)-N,N-Dibutyl-3-[{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indo-
l-1-ylmethyl]-phenyl}-acrylamide;
[0165] (E)-N-Butyl,
N'-methyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methy-
l-indol-1-ylmethyl]-phenyl}-acrylamide;
[0166]
(E)-Morpholinino-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indo-
l-ylmethyl]-phenyl}-acrylamide;
[0167]
(E)-3-(4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-
-phenyl)-acrylamide;
[0168]
(E)-N,Methyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1--
ylmethyl]-phenyl}acrylamide;
[0169]
(E)-N,N-Dibutyl-3-{4-[5-hydroxy-2-(4-fluoro-phenyl)-3-methyl-indol--
1-ylmethyl]-phenyl}-acrylamide;
[0170]
(E)-N-Buty1,N'-Methyl-3-{4-[5-hydroxy-2-(4-fluoro-phenyl)-3-methyl--
indol-1-ylmethyl]-phenyl}-acrylamide;
[0171] as well as the pharmaceutically acceptable salts and esters
thereof.
[0172] The compounds of this second subset or subgroup of
substituted indole compounds can be produced by the methods
described in EP 0 802 184 A1, published Oct. 22, 1997, which is
incorporated herein by reference, or by other methods known in the
art.
[0173] A third subset of substituted indole compounds useful with
the present invention include those of the formulae VII and VIII:
16
[0174] wherein n is 1, 2 or 3 and the variable substituents
including R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, n,
X, and Y are as defined above, or a pharmaceutically acceptable
salt thereof.
[0175] Among the preferred compounds of this third subset of
substituted indoles are:
[0176]
2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(3-N,N-dimethyl-1-yl-prop-1-ynyl-
)-benzyl]-1H-indol-5-ol;
[0177]
2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(3-piperidin-1-yl-prop-1-ynyl)-b-
enzyl]-1H-indol-5-ol;
[0178] and
[0179]
2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(3-pyrrolidin-1-yl-prop-1-ynyl)--
benzyl]-1H-indol-5-ol;
[0180] or pharmaceutically acceptable salts or esters thereof.
[0181] The compounds of this third subset or subgroup of
substituted indole compounds can be produced by the methods
described in U.S. Pat. No. 5,880,137 (Miller et al.), which is
incorporated herein by reference, or by other methods known in the
art.
[0182] Within each of the first, second and third subsets of
substituted indole compounds of this invention are further
subdivisions of more preferred substituted indole compounds having
the general structures I through VIII, above, wherein:
[0183] R.sub.1 is selected from H, OH or the C.sub.1-C.sub.12
esters or alkyl ethers thereof, halogen; R.sub.2, R.sub.3, R.sub.4,
RD5A, and R.sub.6 are independently selected from H, OH or the
C.sub.1-C.sub.12 esters or alkyl ethers thereof, halogen, cyano,
C.sub.1-C.sub.6 alkyl, or trihalomethyl, preferably
trifluoromethyl, with the proviso that, when R.sub.1 is H, R.sub.2
is not OH;
[0184] X is selected from H, C.sub.1-C.sub.6 alkyl, cyano, nitro,
trifluoromethyl, halogen;
[0185] Y is the moiety 17
[0186] R.sub.7 and R.sub.8 are selected independently from H,
C.sub.1-C.sub.6 alkyl, or combined by --(CH.sub.2).sub.p--, wherein
p is an integer of from 2 to 6, so as to form a ring, the ring
being optionally substituted by up to three substituents selected
from the group of hydrogen, hydroxyl, halo, C.sub.1-C.sub.4 alkyl,
trihalomethyl, C.sub.1-C.sub.4 alkoxy, trihalomethoxy,
C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl,
C.sub.1-C.sub.4 alkylsulfonyl, hydroxy (C.sub.1-C.sub.4)alkyl,
--CO.sub.2H, --CN, --CONH(C.sub.1-C.sub.4), --NH.sub.3,
C.sub.1-C.sub.4 alkylamino, C.sub.1-C.sub.4 dialkylamino,
--NHSO.sub.2(C.sub.1-C.sub.4), --NHCO(C.sub.1-C.sub.4), and
--NO.sub.3;
[0187] and the pharmaceutically acceptable salts thereof.
[0188] The rings formed by a concatenated R.sub.7 and R.sub.8,
mentioned above, may include, but are not limited to, aziridine,
azetidine, pyrrolidine, piperidine, hexamethyleneamine or
heptamethyleneamine rings.
[0189] The most preferred substituted indole compounds of the
present invention are those having the structural formulas I
through VIII, above, wherein R.sub.1 is OH; R.sub.2-R.sub.6 are as
defined above; X is selected from the group of Cl, NO.sub.2, CN,
CF.sub.3, or CH.sub.3; and Y is the moiety 18
[0190] and R.sub.7 and R.sub.8 are concatenated together as
--(CH.sub.2).sub.r--, wherein r is an integer of from 4 to 6, to
form a ring optionally substituted by up to three substituents
selected from the group of hydrogen, hydroxyl, halo,
C.sub.1-C.sub.4 alkyl, trihalomethyl, C.sub.1-C.sub.4 alkoxy,
trihalomethoxy, C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4
alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl, hydroxy
(C.sub.1-C.sub.4)alkyl, --CO.sub.2H, --CN,
--CONH(C.sub.1-C.sub.4)alkyl, --NH.sub.2, C.sub.1-C.sub.4
alkylamino, di(C.sub.1-C.sub.4)alkylamino,
--NHSO.sub.2(C.sub.1-C.sub.4)alkyl, --NHCO(C.sub.1-C.sub.4)alkyl,
and --NO.sub.2;
[0191] and the pharmaceutically acceptable salts thereof.
[0192] In another embodiment of the substituted indoles of this
invention, when R.sub.7 and R.sub.8 are concatenated together as
--(CH.sub.2).sub.p--, wherein p is an integer of from 2 to 6,
preferably 4 to 6, the ring so formed is optionally substituted
with 1-3 substituents selected from a group containing
C.sub.1-C.sub.3 alkyl, trifluoromethyl, halogen, hydrogen, phenyl,
nitro, --CN.
[0193] The invention includes sulfate, sulfamates and sulfate
esters of phenolic groups in these substituted indoles. Sulfates
can be readily prepared by the reaction of the free phenolic
compounds with sulfur trioxide complexed with an amine such as
pyridine, trimethylamine, triethylamine, etc. Sulfamates can be
prepared by treating the free phenolic compound with the desired
amino or alkylamino or dialkylamino sulfamyl chloride in the
presence of a suitable base such as pyridine. Sulfate esters can be
prepared by reaction of the free phenol with the desired
alkanesulfonyl chloride in the presence of a suitable base such as
pyridine. Additionally, this invention includes compounds
containing phosphates at the phenol as well as dialkyl phosphates.
Phosphates can be prepared by reaction of the phenol with the
appropriate chlorophosphate. The dialkylphosphates can be
hydrolyzed to yield the free phosphates. Phosphinates are also
claimed where the phenol is reacted with the desired
dialkylphosphinic chloride to yield the desired dialkylphosphinate
of the phenol.
[0194] The invention includes acceptable salt forms of the
substituted indoles formed from the addition reaction with either
inorganic or organic acids. Inorganic acids such as hydrochloric
acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric
acid, nitric acid useful as well as organic acids such as acetic
acid, propionic acid, citric acid, maleic acid, malic acid,
tartaric acid, phthalic acid, succinic acid, methanesulfonic acid,
toluenesulfonic acid, napthalenesulfonic acid, camphorsulfonic
acid, benzenesulfonic acid are useful. It is known that compounds
possessing a basic nitrogen can be complexed with many different
acids (both protic and non-protic) and usually it is preferred to
administer a compound of this invention in the form of an acid
addition salt. Additionally, this invention includes quaternary
ammonium salts of the compounds herein. These can be prepared by
reacting the nucleophilic amines of the side chain with a suitably
reactive alkylating agent such as an alkyl halide or benzyl
halide.
[0195] It is understood that the dosage, regimen and mode of
administration of these compounds will vary according to the extent
of the malady and the individual being treated and will be subject
to the judgement of the medical practitioner involved. It is
preferred that the administration of one or more of the SSRIs and
substituted indole compounds herein begin at a low dose and be
increased until the desired effects are achieved.
[0196] Effective administration of these compounds may be given at
an effective dose of from about 0.1 mg/day to about 500 mg/day.
Preferably, administration will be from about 1 mg/day to about 200
mg/day in a single dose or in two or more divided doses. Such doses
may be administered in any manner useful in directing the active
compounds herein to the recipient's bloodstream, including orally,
parenterally (including intravenous, intraperitoneal and
subcutaneous injections), and transdermally. For the purposes of
this disclosure, transdermal administrations are understood to
include all administrations across the surface of the body and the
inner linings of bodily passages including epithelial and mucosal
tissues. Such administrations may be carried out using the present
compounds, or pharmaceutically acceptable salts thereof, in
lotions, creams, foams, patches, suspensions, solutions, and
suppositories (rectal and vaginal).
[0197] When the active ingredient in the formulations and methods
of this invention is 1-[4-(2-Azepan-1
yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-m- ethyl-1H-indol-5-ol,
also known as TSE-424, or a pharmaceutically acceptable salt
thereof, the preferred daily dosage for oral delivery is from about
0.1 to about 50 mg, preferably from about 2.5 to about 40 mg per
day.
[0198] When the active ingredient in the formulations and methods
of this invention is
2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-
-benzyl]-1H-indol-5-ol, also known as ERA-923, or a
pharmaceutically acceptable salt form thereof, the preferred daily
dosage for oral delivery is from about 0.1 to about 200 mg,
preferably from about 2.5 to about 100 mg per day.
[0199] Oral formulations containing the active compounds of this
invention may comprise any conventionally used oral forms,
including tablets, capsules, buccal forms, troches, lozenges and
oral liquids, suspensions or solutions. Capsules may contain
mixtures of the active compound(s) with inert fillers and/or
diluents such as the pharmaceutically acceptable starches (e.g.
corn, potato or tapioca starch), sugars, artificial sweetening
agents, powdered celluloses, such as crystalline and
microcrystalline celluloses, flours, gelatins, gums, etc. Useful
tablet formulations may be made by conventional compression, wet
granulation or dry granulation methods and utilize pharmaceutically
acceptable diluents, binding agents, lubricants, disintegrants,
suspending or stabilizing agents, including, but not limited to,
magnesium stearate, stearic acid, talc, sodium lauryl sulfate,
microcrystalline cellulose, carboxymethylcellulose calcium,
polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan
gum, sodium citrate, complex silicates, calcium carbonate, glycine,
dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate,
lactose, kaolin, mannitol, sodium chloride, talc, dry starches and
powdered sugar. Oral formulations herein may utilize standard delay
or time release formulations to alter the absorption of the active
compound(s). Suppository formulations may be made from traditional
materials, including cocoa butter, with or without the addition of
waxes to alter the suppository's melting point, and glycerin. Water
soluble suppository bases, such as polyethylene glycols of various
molecular weights, may also be used.
[0200] The SSRI compounds of these methods may be administered in
regimens and at dosages known in the art. For instance, venlafaxine
hydrochloride, which is sold by Wyeth-Ayerst Laboratories under the
Effexor.RTM. name, has a recommended initial dosage of 75 mg per
day, which may be increased to a final daily dosage of up to 225
mg. Average administration is from about 140 to about 180 mg per
day. Fluoxetine hydrochloride, marketed by Dista Products Division
of Eli Lilly and Company under the Prozac.RTM. brandname, may be
administered at a daily dosage of from about 20 to about 80 mg.
Paroxetine hydrochloride, offered by SmithKline Beecham, Inc. under
the Paxil.RTM. name, has a recommended daily dosage of from 20 to
50 mg. Sertraline hydrochloride, sold under the Zoloft.RTM. name by
Pfizer, Inc. may be administered at an initial dose of 25 mg per
day and raised to a daily dose of from 50 to 200 mg. Fluvoxamine
maleate, sold under the Luvox.RTM. tradename by Solvay
Pharmaceuticals, Inc., may be given at a starting dose of 50 mg and
raised to a daily dosage range of from 100 to 300 mg/day.
[0201] The joint administration of the two groups of compounds in
these methods will be determined by a medical professional based
upon the condition of the recipient and the malady for which the
prophylaxis or treatment is provided. Administration of the two
compounds may begin simultaneously or one may be introduced into an
ongoing regimen of the other.
[0202] Preferably, the pharmaceutical compositions of the methods
herein are supplied in unit dosage form, e.g. as tablets or
capsules. In such form, the composition is sub-divided in unit dose
containing appropriate quantities of the active ingredient; the
unit dosage forms can be packaged compositions, for example,
packeted powders, vials, ampoules, prefilled syringes or sachets
containing liquids. The unit dosage form can be, for example, a
capsule or tablet itself, or it can be the appropriate number of
any such compositions in package form.
[0203] The substituted indole compound(s) and the SSRI(s) of the
present formulations may be administered in separate dosage units,
such as separate pills, tablets, powders, etc., or combined into
one formulation. When optimum dosages for the indole compounds and
the SSRI of these formulations have been determined, it may
preferable to incorporate both into a single formulation for ease
of administration. It is also understood that the formulations
herein may or may not include other pharmaceutically active
components.
[0204] This invention also includes kits or packages of
pharmaceutical formulations designed for use in the regimens and
methods described herein. These kits are preferably designed for
daily oral administration over the specified term or cycle of
administration, preferably for the number of prescribed oral
administrations per day, and organized so as to indicate a single
oral formulation or combination of oral formulations to be taken on
each day of the regimen or cycle. Preferably each kit will include
oral tablets to be taken on each the days specified, in some
embodiments one oral tablet will contain each of the combined daily
dosages indicated and in other embodiments the administrations of
the separate compounds will be present in separate formulations or
compositions. It is most preferable that the package or kit shall
have a calendar or days-of-the-week designation directing the
administration of the appropriate compositions on the appropriate
day or time.
[0205] A preferred combination of this invention includes
pharmaceutical compositions of
1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-
-methyl-1H-indol-5-ol, or a pharmaceutically acceptable salt
thereof, packaged and/or utilized in combination with venlafaxine,
or a pharmaceutically acceptable salt thereof. Another comprises
2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-i-
ndol-5-ol, or pharmaceutically acceptable salt thereof, packaged
and/or used in combination with venlafaxine, or a pharmaceutically
acceptable salt thereof.
[0206] Solid oral formulations, preferably in the form of a film
coated tablet or capsule, useful for this invention include the
active substituted indole pharmacological agents disclosed herein
in combination with carrier or excipient systems having the
components:
[0207] a) a filler and disintegrant component comprising from about
5% to about 82% by weight (wght) of the total formulation,
preferably between about 30% and about 80% of the formulation, of
which from about 4% to about 40% by weight of the total formulation
comprises one or more pharmaceutically acceptable
disintegrants;
[0208] b) optionally, a wetting agent comprising from about 0.2 to
about 5% of the composition (wght), such as selected from the group
of sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid
esters, polyoxyethylene alkyl ethers, sorbitan fatty acid esters,
polyethylene glycols, polyoxyethylene castor oil derivatives,
docusate sodium, quaternary ammonium compounds, sugar esters of
fatty acids and glycerides of fatty acids;
[0209] c) a lubricant comprising from about 0.2% to about 10% of
the composition (wght), such as selected from the group of
magnesium stearate or other metallic stearates (e.g. calcium
stearate or zinc stearate), fatty acid esters (e.g. sodium stearyl
fumarate), fatty acids (e.g. stearic acid), fatty alcohols,
glyceryl behenate, mineral oil, parrafins, hydrogenated vegetable
oils, leucine, polyethylene glycols, metallic lauryl sulfates and
sodium chloride; and
[0210] d) optionally, a glidant comprising from about 0.1% to about
10% (wght) of the composition, the glidant selected from those
known in the art, including from the group of silicon dioxide,
talc, metallic stearates, calcium silicate, or metallic lauryl
sulfates.
[0211] While the formulations described herein may be used in an
uncoated or non-encapsulated solid form, preferably the final
compositions are coated or encapsulated. The pharmacological
compositions may be optionally coated with a film coating,
preferably comprising from about 0.3% to about 8% by weight of the
overall composition. Film coatings useful with the present
formulations are known in the art and generally consist of a
polymer (usually a cellulosic type of polymer), a colorant and a
plasticizer. Additional ingredients such as wetting agents, sugars,
flavors, oils and lubricants may be included in film coating
formulations to impart certain characteristics to the film coat.
The compositions and formulations herein may also be combined and
processed as a solid, then placed in a capsule form, such as a
gelatin capsule.
[0212] The filler component listed above may utilize the filler or
binder components known in the art for solid oral formulations.
Pharmaceutically acceptable fillers or binding agents selected from
those known in the art including, but not limited to, lactose,
microcrystalline cellulose, sucrose, mannitol, calcium phosphate,
calcium carbonate, powdered cellulose, maltodextrin, sorbitol,
starch, or xylitol.
[0213] In conjunction with or in place of the materials listed
above for the filler component, the present formulations utilize
disintegrant agents. These disintegrants may be selected from those
known in the art, including pregelatinized starch and sodium starch
glycolate. Other useful disintegrants include croscarmellose
sodium, crospovidone, starch, alginic acid, sodium alginate, clays
(e.g. veegum or xanthan gum), cellulose floc, ion exchange resins,
or effervescent systems, such as those utilizing food acids (such
as citric acid, tartaric acid, malic acid, fumaric acid, lactic
acid, adipic acid, ascorbic acid, aspartic acid, erythorbic acid,
glutamic acid, and succinic acid) and an alkaline carbonate
component (such as sodium bicarbonate, calcium carbonate, magnesium
carbonate, potassium carbonate, ammonium carbonate, etc.). The
disintegrant(s) useful herein will comprise from about 4% to about
40% of the composition by weight, preferably from about 15% to
about 35%, more preferably from about 20% to about 35%. Some
components may have multiple functions in the formulations of this
invention, acting e.g. as both a filler and a disintegrant, such a
component may be referred to as a filler disintegrant and its
function in a specific formulation may be singular even though its
properties may allow multiple functionality.
[0214] The pharmaceutical formulations and carrier or excipient
systems herein preferably also contain an antioxidant or a mixture
of antioxidants, most preferably ascorbic acid. Other antioxidants
which may be used include sodium ascorbate and ascorbyl palmitate,
preferably in conjunction with an amount of ascorbic acid. A
preferable range for the antioxidant(s) is from about 0.5% to about
15% by weight, most preferably from about 0.5% to about 5% by
weight.
[0215] Among the formulations of this invention are pharmaceutical
formulations containing a pharmaceutically effective amount of an
active pharmacological agent and a carrier or excipient system
comprising:
[0216] a) a filler and disintegrant component comprising between
about 50% and about 87% of the formulation, with from about 4% to
about 40% of the formulation comprising one or more disintegrant
agents;
[0217] b) a wetting agent comprising between about 0.5% and about
2.7% of the formulation;
[0218] c) a lubricant comprising between about 0.2% and about 5.5%
of the formulation;
[0219] and
[0220] d) a glidant comprising between about 0.1% and about 5.5% of
the formulation.
[0221] The percentages listed in the formulations above indicate
percentages by weight of the total weight of the components listed
from a) to d). The formulations above also preferably contain an
optional antioxidant component, preferably ascorbic acid, at a
concentration of from about 0.5% to about 5.5% by weight of the
formulation. The formulations are also preferably contained within
a pharmaceutically acceptable capsule, such as a gel capsule, or
coated with a film coating comprising from about 0.3% to about 8%
by weight of the formulation.
[0222] This invention also comprises a pharmaceutical carrier or
excipient systems useful in pharmaceutical compositions utilizing
as an active ingredient one or more of the compounds described
herein, or a pharmaceutically acceptable salt thereof, as described
herein. These pharmaceutical carrier or excipient systems comprise,
by weight:
[0223] a) a filler and disintegrant component comprising between
about 54% and about 80% of the formulation, with the disintegrant
agent(s) therein comprising from about 4% to about 40% by weight of
the overall formulation;
[0224] b) a wetting agent comprising between about 0.55% and about
2.5% of the formulation;
[0225] c) a lubricant comprising between about 0.2% and about 5.5%
of the formulation;
[0226] and
[0227] d) a glidant comprising between about 0.1% and about 5.0% of
the formulation.
[0228] The more preferred carrier or excipient systems above also
optionally and preferably contain an antioxidant component,
preferably ascorbic acid, at a concentration of from about 0.1% to
about 5.0% by weight.
[0229] Among the carrier or excipient systems of this invention are
those comprising:
[0230] a) a filler and disintegrant component, as described above,
comprising between about 50% and about 87% of the formulation, the
disintegrant(s) therein comprising from about 25% to about 35% of
the formulation, by weight;
[0231] b) a wetting agent comprising between about 0.55% and about
2.7% of the formulation;
[0232] c) a lubricant comprising between about 0.2% and about 5.5%
of the formulation;
[0233] d) a glidant comprising between about 0.1% and about 5.5% of
the formulation; and
[0234] e) an antioxidant component, preferably ascorbic acid, at a
concentration of from about 0.1% to about 5.5% by weight.
EXAMPLE 1
[0235] TSE-424 Acetate-Rapid Dissolution Formulations
1 without with Ascorbic Ascorbic Ingredient Acid Acid TSE-424
acetate, 10.00 10.00 micronized* Lactose NE fast flow 33.10 31.60
Microcrystalline 25.00 25.00 Cellulose, NF (Avicel PH101) Starch
1500 20.00 20.00 Sodium Lauryl Sulfate 1.50 1.50 NF Sodium Starch
Glycolate 10.00 10.00 Ascorbic Acid USP -- 1.5 Syloid 244 FP 0.15
0.15 Magnesium Stearate 0.25 0.25 *Amount in formula is adjusted
for actual potency of TSE-424 as free base. Corresponding
adjustment made with Lactose.
[0236] The formulations given above in Table 1 were prepared by
incorporating a portion of the excipients in the granulation and a
portion is also added in the final blending steps as dry powders. A
dissolution profile generated for the formulations demonstrated
almost 90% release of the drug in 30 minutes. Thus, the unique
combination of disintegrants and soluble diluents plus the
incorporation of both granulated and powdered solids into the
composition ensures the fastest release of drug.
[0237] Wet granulation of the formulations as described in Table 1
may be carried out by mixing the drug and ascorbic acid with a
portion of the lactose, microcrystalline cellulose, pregelatinized
starch and sodium starch glycolate. The sodium lauryl sulfate is
dissolved in the water and used to granulate the mixture of powders
in a high shear mixer. The granulation is dried in a fluid bed
dryer to a moisture of 2-3%. The particle size of the dried
granulation is controlled by passing through a mill equipped with
knife-edged blades and using a 20- or 30-mesh screen. The silicon
dioxide and remaining lactose, microcrystalline cellulose,
pregelatinized starch, and sodium starch glycolate are mixed with
the milled granulation in a tumble-type mixer. The final blend is
prepared by adding magnesium stearate to the tumble-type mixer and
mixing. Compression is carried out on a rotary tablet press using
appropriate size tooling. Coating is performed in conventional
coating pans and applying the coating suspension to achieve a
suitable film coat.
EXAMPLE 2
[0238] Modified TSE-424 Formulation
2 % w/w 5% Ingredient granulation TSE-424 acetate, micronized.sup.a
5.00 Lactose NF 41.00 Microcrystalline Cellulose, NF 35.00
Pregelatinized Starch NF 10.00 Sodium Lauryl Sulfate NF 1.50
I-Ascorbic Acid USP 1.50 Sodium Starch Glycolate NF 5.50 Magnesium
Stearate NF 0.50 Pur. Water USP.sup.b qs .sup.aAmount in formula is
adjusted for actual potency of TSE-424 as free base. Corresponding
adjustment made with Lactose. .sup.bUsed in process but does not
appear in the final product.
EXAMPLE 3
[0239] ERA-923 Formulations
3 % w/w 10.86% 11.19% 17.5% 17.9% granula- granula- granula-
granula- Ingredient tion tion tion tion ERA-923, micronized.sup.a
10.867 11.193 17.489 17.909 Lactose NF 29.000 29.000 17.380 18.000
Microcrystalline Cellulose, 40.633 42.807 38.000 39.090 NF
Pregelatinized Starch NF 10.000 10.000 14.630 15.000 Sodium Lauryl
Sulfate NF 2.500 -- 2.500 -- I-Ascorbic Acid USP 1.500 1.500 1.500
1.500 Sodium Starch Glycolate 5.000 5.000 8.000 8.000 NF Magnesium
Stearate NF 0.500 0.500 0.500 0.500 Pur. Water USP.sup.b qs qs qs
qs .sup.aAs the Hydrochloride Monohydrate. Quantity is adjusted
based on the actual potency (theory = 89.34%). .sup.bUsed in
process but does not appear in the final product.
[0240] ERA-923 tablets are compressed to a tablet weight of up to
640 mg to achieve the target dose (up to 100 mg). Tablets may then
be film coated.
EXAMPLE 4
[0241] TSE-424 at 5% Granulation
[0242] A preferred carrier or excipient system for formulating a
granulation of from about 2 to about 8% by weight of one of the
active pharmacological agents of this invention, preferably about
5%, may be produced utilizing the carrier or excipient components
on a weight percentage; lactose from about 32% to about 38%,
microcrystalline cellulose from about 32% to about 38%,
pregelatinized starch from about 12% to about 16%, ascorbic acid
from about 1% to about 2%, sodium lauryl sulfate from about 1% to
about 2%, sodium starch glycolate from about 4% to about 8%,
silicon dioxide from about 0.1% to about 0.2% and magnesium
stearate from about 0.3% to about 0.7%.
[0243] A formulation of this invention utilizing TSE-424 as the
active ingredient at a 5% granulation was prepared utilizing the
components listed below in a granulation part of components and a
dry part.
4 Item No. Ingredients Mg/Unit Granulation Part: 1 TSE-424 acetate
5.00 2 Lactose NF 26.60 3 Microcrystalline Cellulose NF 25.00 4
Pregelatinized Starch NF 10.00 5 Ascorbic Acid USP 1.50 6 Sodium
Lauryl Sulfate NF 1.50 7 Sodium Starch Glycolate NF 4.00 8 Water,
Purified USP Q.S. 73.60 Dry Part: 9 Lactose NF (fast flo) 9.75 10
Microcrystalline Cellulose NF 10.00 11 Pregelatinized Starch NF
4.00 12 Sodium Starch Glycolate NF 2.00 13 Silicon Dioxide NF 0.15
14 Magnesium Stearate NF 0.50 100.00
[0244] A film coat of White Opadry I (YS-1-18027-A) was applied to
the tablets, which were compressed as follows:
5 Dose of TSE-424 tablet weight, mg mg of film coat applied/tablet
5 mg 100 6.0 10 mg 200 8.0 20 mg 400 13.0
* * * * *